SPDR S&P Biotech ETF
432 hedge funds and large institutions have $5.71B invested in SPDR S&P Biotech ETF in 2018 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 174 increasing their positions, 119 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
432
Holders Change
+1
Holders Change %
+0.23%
% of All Funds
9.89%
Holding in Top 10
20
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-9.09%
% of All Funds
0.46%
New
56
Increased
174
Reduced
119
Closed
50
Calls
$762M
Puts
$1.86B
Net Calls
-$1.1B
Net Calls Change
-$562M
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$185M |
| 2 |
JPMorgan Chase & Co
New York
|
+$156M |
| 3 |
Rafferty Asset Management
New York
|
+$48.1M |
| 4 |
Goldman Sachs
New York
|
+$43.6M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$39.9M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$221M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$127M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$110M |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$43.6M |
| 5 |
AssetMark Inc
Concord,
California
|
-$41.5M |
